330 Collins Street
30 articles with Clinuvel
In the search for a preventative treatment of skin cancers, including melanoma, it is imperative to understand and treat DNA damage caused by ultraviolet radiation.
CLINUVEL progresses innovative DNA Repair ProgramDrug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk
CLINUVEL PHARMACEUTICALS LTD announced the progression of its drug SCENESSE® to treat the disease xeroderma pigmentosum.
CLINUVEL Opens VALLAURIX R&D Centre In SingaporeBespoke Research & Development Centre to advance innovative pharmaceutical and OTC products
The CLINUVEL Group announced the opening of its state-of-the-art centralised Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd.
PRÉNUMBRA® - CLINUVEL's Second Afamelanotide FormulationDrug to be evaluated in patients with acute and systemic diseases
CLINUVEL PHARMACEUTICALS revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development.
SCENESSE® to be Prescribed in ChinaCLINUVEL and Winhealth Pharma sign Collaboration Agreement to treat erythropoietic protoporphyria (EPP)
Australian-based company CLINUVEL is launching SCENESSE® in the People’s Republic of China for the treatment of the rare genetic metabolic disorder erythropoietic protoporphyria.
Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or burning reactions from exposure to light, are welcoming an approved treatment for the first time ever.
Scenesse is an under-the-skin implant. The drug is the company’s only approved product.
FDA to Review Australian Drug for Genetic Disorder of Absolute Light IntoleranceHistoric treatment proposed for rare disease causing burns, ulcerations and lifelong isolation of patients forced to live in the dark
In a landmark case, the US Food and Drug Administration (FDA) has begun a review of an innovative drug developed for patients who carry a rare genetic blood disorder known as erythropoietic protoporphyria (EPP).
Clinuvel Release: NICE’s Technical Team Invited Stakeholders With An Interest In The Treatment Of erythropoietic protoporphyria (EPP)
Clinuvel Announces Positive Results From Pivotal European Phase III Study: Endpoints Demonstrate Clinically Relevant Treatment Effect of Afamelanotide
Clinuvel Announces Positive Results of First Phase II US Study of SCENESSE® in Orphan Disease Erythropoietic Protoporphyria (EPP)